The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 298.50
Bid: 295.50
Ask: 298.50
Change: -3.50 (-1.16%)
Spread: 3.00 (1.015%)
Open: 300.00
High: 300.00
Low: 297.00
Prev. Close: 302.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Synthomer announces the pricing of senior notes

19 Jun 2020 07:00

RNS Number : 4836Q
Synthomer PLC
19 June 2020
 

19 June 2020

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES

OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

Synthomer plc

 

Synthomer announces the pricing of €520 million 3⅞% senior notes due 2025

 

Synthomer plc ("Synthomer") today announces that it has completed the successful pricing of €520.0 million in aggregate principal amount of 3⅞% senior notes due 2025 (the "Notes"). The Notes will be issued at par.

 

The offering is expected to close on 25th June 2020. The Notes are expected to be admitted to the London Stock Exchange's International Securities Market. The proceeds from the offering will be used (i) to repay borrowings under Synthomer's 2019 bridge facility, which was introduced as part of the financing arrangements for the acquisition of OMNVOA Solutions Inc., and (ii) to pay certain costs, fees and expenses related to the offering of Notes.

 

Stephen Bennett, Synthomer plc Chief Financial Officer, commented:

"Synthomer now has in place a long-term financing structure, together with a strong balance sheet and significant leverage covenant headroom. The Group has significant liquidity underpinned by its 2024 committed unsecured 5 year €460 million revolving credit facility, $260 million term loan bank facility and now the €520 million bond due 2025."

 

Cautionary Statement

 

The Notes will be offered only to qualified institutional buyers pursuant to Rule 144A and outside the United States pursuant to Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act"), subject to prevailing market and other conditions. There is no assurance that the offering will be completed or, if completed, as to the terms on which it is completed. The Notes to be offered have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or unless pursuant to an applicable exemption from the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

 

The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ("EEA") or the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); (ii) a person that is not a qualified investor as defined in Article 2(e) of the Prospectus Regulation; or (iii) a customer within the meaning of Directive (EU) 2016/97 (as amended, the "Insurance Distribution Directive"), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II.

 

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129 (as amended or superseded, the "Prospectus Regulation"). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Regulation from the requirement to produce a prospectus for offers of securities.

 

In the United Kingdom, this announcement is directed only at (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) persons to whom it would otherwise be lawful to distribute them, all such persons together being referred to as "Relevant Persons." The Notes are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be engaged in only with, Relevant Persons.

 

MiFID II professionals/ECPs-only/ No PRIIPs KID - Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA or the United Kingdom.

 

Neither the content of Synthomer's website nor any website accessible by hyperlinks on Synthomer's website is incorporated in, or forms part of, this announcement. The distribution of this announcement into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

This announcement contains inside information within the meaning of Regulation (EU) No 596/2014 of 16 April 2014 on market abuse.

 

Forward-Looking Statements

 

This press release may include forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", ‟estimates", ‟anticipates", "expects", ‟intends", ‟may", ‟will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts and include statements regarding Synthomer's or its affiliates' intentions, beliefs or current expectations concerning, among other things, Synthomer's or its affiliates' results of operations, financial condition, liquidity, prospects, growth, strategies and the industries in which they operate. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that Synthomer's or its affiliates' actual results of operations, financial condition and liquidity, and the development of the industries in which they operate may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if Synthomer's or its affiliates' results of operations, financial condition and liquidity, and the development of the industries in which they operate are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.

 

The forward-looking statements and information contained in this announcement are made as of the date hereof and Synthomer undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

 

-ENDS-

 

Enquiries:

 

Synthomer plc

Calum MacLean, Chief Executive Officer

Stephen Bennett, Chief Financial Officer

Tim Hughes, President, Corporate Development

Tel: + 44 7764 859147

 

 

Teneo

Charles Armitstead / Matt Denham

Tel: + 44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLMITMTJBMJM
Date   Source Headline
8th Mar 20184:39 pmRNSDirector/PDMR Shareholding
8th Mar 20184:37 pmRNSDirector/PDMR Shareholding
5th Mar 20182:43 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSResults for the year ended 31 December 2017
12th Feb 201810:27 amRNSDirector Declaration
1st Feb 20187:00 amRNSCompletion of the acquisition of BASF Pischelsdorf
2nd Jan 20187:00 amRNSDisposal of Synthomer Leuna Gmbh facility
13th Dec 20172:55 pmRNSDirector Declaration
4th Dec 20175:31 pmRNSHolding(s) in Company
27th Nov 20179:29 amRNSHolding(s) in Company
10th Nov 20179:40 amRNSDirectorate Change
9th Nov 201710:03 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSQ3 Trading update
9th Oct 20179:23 amRNSDirector Declaration
28th Sep 20177:00 amRNSAcquisition of BASF Pischelsdorf
18th Sep 20172:00 pmRNSHolding(s) in Company
17th Aug 201712:54 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSInterim Results for the 6 months ended 30 Jun 2017
1st Aug 20173:57 pmRNSHolding(s) in Company
10th Jul 201710:33 amRNSDirector/PDMR Shareholding
9th Jun 20173:14 pmRNSDirector/PDMR Shareholding
8th May 201712:40 pmRNSDirector/PDMR Shareholding
8th May 201712:24 pmRNSDirector/PDMR Shareholding
27th Apr 20174:05 pmRNSDirector Declaration
27th Apr 20172:53 pmRNSResult of AGM
27th Apr 20177:00 amRNSQ1 Trading update
27th Mar 20179:54 amRNSAnnual Financial Report
6th Mar 20177:02 amRNSAcquisition of Perstorp Belgium
6th Mar 20177:00 amRNSFinal Results
23rd Feb 20174:31 pmRNSAmendment TR-1 notification
8th Feb 20174:13 pmRNSHolding(s) in Company
6th Feb 201711:48 amRNSHolding(s) in Company
20th Jan 20177:00 amRNSQ4 and FY trading update
13th Dec 201610:57 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSCapital Markets Day
28th Nov 20169:51 amRNSHolding(s) in Company
18th Nov 20164:56 pmRNSHolding(s) in Company
16th Nov 201610:15 amRNSHolding(s) in Company
10th Nov 20162:23 pmRNSHolding(s) in Company
9th Nov 20164:18 pmRNSDirector/PDMR Shareholding
9th Nov 20167:00 amRNSQ3 Trading update
3rd Oct 20162:11 pmRNSHolding(s) in Company
26th Sep 20169:25 amRNSHolding(s) in Company
14th Sep 20163:10 pmRNSHolding(s) in Company
14th Sep 20163:01 pmRNSHolding(s) in Company
11th Aug 20161:15 pmRNSDisposal
9th Aug 20167:00 amRNSInterim Results for six months ended 30 June 2016
7th Jul 201611:50 amRNSHolding(s) in Company
7th Jul 201610:28 amRNSDirector/PDMR Shareholding
5th Jul 201611:57 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.